# Key Information Document

MAREX Financial Products

## Purpose

**This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.**

**You are about to purchase a product that is not simple and may be difficult to understand.**

## Product

| | |
|---|---|
| **Product name** | Credit Linked Certificate Linked to Assicurazioni Generali |
| **Product identifier** | ISIN: IT0006776576 |
| **PRIIP manufacturer** | Marex Financial (www.marexfp.com) |
| | Call +44 20 8050 3568 or +39 02 3056 9828 for more information. |
| **Competent authority of the PRIIP manufacturer** | Authorised and regulated by the U.K. Financial Conduct Authority |
| **Date and time of production** | 19 June 2026 7:10 Rome local time |

## 1. What is this product?

### Type

English law governed multi-asset class-linked certificates / Return depends on the performance of the reference entity / No capital protection against market risk

### Term

The product has a fixed term and will be due on 11 July 2035, subject to the occurrence of a credit event.

### Objectives

(Terms that appear in **bold** in this section are described in more detail in the table(s) below.)

The product is designed to provide a return in the form of (1) regular interest payments and (2) a cash payment on termination of the product. However, whether interest is payable and the timing and amount of any cash payment upon termination will depend on whether or not one or more credit events are determined to have occurred during the **credit observation period**. Your initial investment is not protected. You may not make any profit and you may lose some or all of your initial investment.

Coupon:

1. If no credit event has occurred, on each **coupon payment date** you will receive a coupon payment calculated by multiplying the **product notional amount** by the applicable coupon rate and then applying the relevant **day count fraction** to adjust this amount to reflect the length of the relevant **coupon period**.

| *Coupon payment dates* | *Coupon rates* |
|---|---|
| 21 June 2027 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 20 June 2028 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 20 June 2029 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 20 June 2030 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 20 June 2031 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 21 June 2032 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 20 June 2033 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| 20 June 2034 | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |
| Maturity date | A per annum rate equal to 3M EURIBOR plus 2.10%, subject to a floor of 2.10% |

2. If a credit event occurs, no further coupon payments will be made following the **coupon payment date** immediately preceding the **credit determination date**.

Principal redemption:

1. If no credit event has occurred, on the **maturity date** you will receive a cash payment equal to EUR 10,000.00.
2. If a credit event occurs, on the **maturity date** you will receive EUR 0.

Credit event: The **reference entity** experiences a credit event if one of the events listed below occurs. A **CDDC**, or the **product calculation agent**, will determine whether one of these events has occurred.

1. Failure to Pay: the **reference entity** fails to make payments due on its debt above a prescribed threshold.
2. Bankruptcy: the **reference entity** experiences insolvency, bankruptcy or related events.
3. Restructuring: the **reference entity**'s debt is restructured on terms that are detrimental to the holder(s) of the relevant debt in a form that is binding on all holder(s).

Extension: The **product calculation agent** may extend the **credit observation end date** and the **maturity date** in certain circumstances to establish whether or not a credit event has occurred. In these circumstances, termination of the product may be delayed and the **credit observation period** may end after the originally scheduled **maturity date**.

Under the product terms, certain dates specified above and below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

In addition to the consequences that result from the occurrence of a credit event, the product terms also provide that if certain other exceptional events occur (1) adjustments may be made to the product, (2) certain fallback provisions may apply and/or (3) the issuer may terminate the product early fully or in part. These events are specified in the product terms and principally relate to the **reference entity**, the product and the issuer. The return (if any) you receive on an early redemption following the occurrence of an exceptional event will be different and is likely to be less than the amount you invested.

When purchasing this product during its lifetime, the purchase price may include accrued coupon on a pro rata basis.



DocHub DocID: ebc80309-726e-4a03-9d62-991101036e4d

| | | | |
|---|---|---|---|
| **Reference entity** | Assicurazioni Generali (Debt Seniority: Subordinated) | **Maturity date / term** | 11 July 2035 (subject to possible delay as described above) |
| **Reference entity transaction type** | Standard Subordinated European Insurance Corporate | **Unwind costs** | An amount reflecting the cost of terminating the product following the occurrence of the **credit event** |
| **Reference rate** | 3M EURIBOR<br>The level of the reference rate for any **coupon period** will be determined by reference to LSEG screen page <EURIBOR3MD=> at 11:00 a.m. (Frankfurt am Main local time) 2 TARGET business days prior to the beginning of that **coupon period** | **Credit observation period start date** | Sixty calendar days prior to the **trade date** |
| **Underlying market** | Credit and Interest rates | **Trade date** | 16 June 2026 |
| **Product notional amount** | EUR 10,000.00 | **Credit observation period end date** | 11 July 2035 (subject to possible delay as described above) |
| **Product currency** | Euro (EUR) | **Credit observation period** | The period commencing (and including) on the **Credit observation period start date** and ending on (and including) the **Credit observation period end date** |
| **Recovery rate** | 0.00% | **Credit determination date** | Either the date on which the **CDDC** is asked to determine whether the relevant credit event has occurred or, the date on which the **product calculation agent** (or other relevant transaction party) gives notice that a credit event has occurred |
| **CDDC** | A Credit Derivatives Determinations Committee established under the relevant Determination Committee Rules | **Coupon period** | Each period from, and including, a **coupon payment date** (or the **issue date**, in the case of the initial coupon period) to, but excluding, the next **coupon payment date** (or the **maturity date**, in the case of the final coupon period) |
| **Product calculation agent** | Marex Financial | **Day count fraction** | Actual/360 |
| **Issue date** | 19 June 2026 | | |

### Intended retail client

The product is intended to be offered to retail investors who fulfil all of the criteria below:

1. they have the ability to make an informed investment decision through sufficient knowledge and understanding of the product and its specific risks and rewards, either independently or through professional advice, and they may have experience of investing in and/or holding a number of similar products providing a similar market exposure;
2. they expect the reference entity to perform in a way that generates a positive return. They have a long investment horizon;
3. they are able to bear a total loss of their initial investment, consistent with the redemption profile of the product at maturity (market risk);
4. they accept the risk that the issuer could fail to pay or perform its obligations under the product irrespective of the redemption profile of the product (credit risk);
5. they are willing to accept a level of risk of 6 out of 7 to achieve potential returns, which reflects the second highest risk (as shown in the summary risk indicator below which takes into account both market risk and credit risk).

## 2. What are the risks and what could I get in return?

### Risk indicator



**The risk indicator assumes you keep the product until 11 July 2035. The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or may have to sell at a price that significantly impacts on how much you get back.**

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are unlikely to impact our capacity to pay you.

Inflation erodes the purchasing value of cash over time and this may result in the decline in real terms of any capital reimbursed or interest you may be paid under the investment.

If we are not able to pay you what is owed, you could lose your entire investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

### Performance scenarios

**What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.**

**The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.**

| | | |
|---|---|---|
| ***Recommended holding period:*** | **9 years** | |
| ***Example investment:*** | EUR 10,000 | |
| ***Scenarios*** | ***If you exit after 1 year*** | ***If you exit after 9 years (Recommended holding period)*** |



DocHub DocID: ebc80309-726e-4a03-9d62-991101036e4d

| | | | |
|---|---|---|---|
| **Minimum** | **There is no minimum guaranteed return. You could lose some or all of your investment.** | | |
| **Stress** | **What you might get back after costs**<br>Average return each year | EUR 3,985<br>-59.44% | EUR 0<br>-100.00% |
| **Unfavourable** | **What you might get back after costs**<br>Average return each year | EUR 7,455<br>-25.03% | EUR 1,326<br>-19.73% |
| **Moderate** | **What you might get back after costs**<br>Average return each year | EUR 8,643<br>-13.33% | EUR 14,111<br>3.82% |
| **Favourable** | **What you might get back after costs**<br>Average return each year | EUR 9,691<br>-3.03% | EUR 15,860<br>5.15% |

The favourable, moderate, unfavourable and stress scenarios represent possible outcomes that have been calculated based on simulations using the reference entity's past performance over a period of up to 5 years and historical default probabilities. The stress scenario shows what you might get back in extreme market circumstances. This product cannot be easily cashed in. If you exit the investment earlier than the recommended holding period, you may have to pay extra costs.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

## 3. What happens if Marex Financial is unable to pay out?

You are exposed to the risk that the issuer might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not covered by any deposit protection scheme.

## 4. What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- EUR 10,000 is invested

| | *If you exit after 1 year* | *If you exit after 9 years* |
|---|---|---|
| **Total costs** | EUR 600 | EUR 550 |
| **Annual cost impact*** | 6.22% | 0.64% each year |

*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 4.46% before costs and 3.82% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Composition of costs

| | **One-off costs upon entry or exit** | **If you exit after 1 year** |
|---|---|---|
| **Entry costs** | 5.50% of the amount you pay when entering this investment. These costs are already included in the price you pay. | EUR 550 |
| **Exit costs** | 0.50% of your investment before it is paid out to you. These costs are already included in the price you receive and are only incurred if you exit before maturity. If you hold the product until maturity, no exit costs will be incurred. | EUR 50 |

## 5. How long should I hold it and can I take money out early?

### Recommended holding period: 9 years

The product aims to provide you with the return described under “1. What is this product?” above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 11 July 2035 (maturity).

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. Save as otherwise disclosed in exit costs (see section "4. What are the costs?" above), no fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

| | | | |
|---|---|---|---|
| **Exchange listing** | EuroTLX | **Price quotation** | Units |
| **Smallest tradable unit** | 1 unit | | |

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

## 6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom, by email to: complaints@marexfp.com or at the following website: www.marexfp.com.

## 7. Other relevant information

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are published on certificati.marex.com, all in accordance with relevant legal requirements. These documents are also available free of charge from Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom. Call +44 (0)208-050-8636 for more information.



DocHub DocID: ebc80309-726e-4a03-9d62-991101036e4d